NZ193221A - Controlled release composition - Google Patents

Controlled release composition

Info

Publication number: NZ193221A
Authority: NZ; New Zealand
Prior art keywords: composition according; prostaglandin; polymeric carrier; weight; polyethylene oxide
Prior art date: 1979-03-21

Application number

NZ193221A

Other languages

English (en)

Inventor

M P Embrey

N B Graham

Original Assignee

M P Embrey

N B Graham

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1979-03-21

Filing date

1980-03-21

Publication date

1984-08-24

1980-03-21 Application filed by M P Embrey, N B Graham filed Critical M P Embrey

1984-08-24 Publication of NZ193221A publication Critical patent/NZ193221A/en

Links

239000000203 mixture Substances 0.000 title claims abstract description 72
238000013270 controlled release Methods 0.000 title claims abstract description 20
229920003171 Poly (ethylene oxide) Polymers 0.000 claims abstract description 62
150000003180 prostaglandins Chemical class 0.000 claims abstract description 42
JOYRKODLDBILNP-UHFFFAOYSA-N urethane group Chemical group NC(=O)OCC JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims abstract description 14
239000013543 active substance Substances 0.000 claims description 32
230000008961 swelling Effects 0.000 claims description 31
238000000034 method Methods 0.000 claims description 27
238000004132 cross linking Methods 0.000 claims description 20
238000002360 preparation method Methods 0.000 claims description 16
239000003814 drug Substances 0.000 claims description 12
229940079593 drug Drugs 0.000 claims description 11
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
239000003795 chemical substances by application Substances 0.000 claims description 6
150000004702 methyl esters Chemical class 0.000 claims description 5
238000001035 drying Methods 0.000 claims description 4
229920000233 poly(alkylene oxides) Polymers 0.000 claims description 4
QAOBBBBDJSWHMU-WMBBNPMCSA-N 16,16-dimethylprostaglandin E2 Chemical compound CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O QAOBBBBDJSWHMU-WMBBNPMCSA-N 0.000 claims description 3
206010008267 Cervical incompetence Diseases 0.000 claims description 2
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
125000003396 thiol group Chemical group [H]S* 0.000 claims description 2
150000007824 aliphatic compounds Chemical class 0.000 claims 2
150000001491 aromatic compounds Chemical class 0.000 claims 1
239000007795 chemical reaction product Substances 0.000 claims 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
229920000642 polymer Polymers 0.000 description 96
239000012948 isocyanate Substances 0.000 description 32
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
239000000243 solution Substances 0.000 description 29
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 27
239000002202 Polyethylene glycol Substances 0.000 description 20
230000000694 effects Effects 0.000 description 19
UPMLOUAZCHDJJD-UHFFFAOYSA-N 4,4'-Diphenylmethane Diisocyanate Chemical compound C1=CC(N=C=O)=CC=C1CC1=CC=C(N=C=O)C=C1 UPMLOUAZCHDJJD-UHFFFAOYSA-N 0.000 description 18
229920001223 polyethylene glycol Polymers 0.000 description 18
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 16
239000000499 gel Substances 0.000 description 16
229960002986 dinoprostone Drugs 0.000 description 14
229940094443 oxytocics prostaglandins Drugs 0.000 description 14
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 14
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
239000000969 carrier Substances 0.000 description 12
150000001875 compounds Chemical class 0.000 description 11
150000002513 isocyanates Chemical class 0.000 description 11
239000000126 substance Substances 0.000 description 11
235000019441 ethanol Nutrition 0.000 description 10
238000010348 incorporation Methods 0.000 description 10
150000002148 esters Chemical class 0.000 description 9
238000009472 formulation Methods 0.000 description 8
239000000463 material Substances 0.000 description 8
-1 polybutylene Polymers 0.000 description 7
ZWVMLYRJXORSEP-UHFFFAOYSA-N 1,2,6-Hexanetriol Chemical compound OCCCCC(O)CO ZWVMLYRJXORSEP-UHFFFAOYSA-N 0.000 description 6
239000004015 abortifacient agent Substances 0.000 description 6
231100000641 abortifacient agent Toxicity 0.000 description 6
239000008363 phosphate buffer Substances 0.000 description 6
239000000376 reactant Substances 0.000 description 6
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
125000001931 aliphatic group Chemical group 0.000 description 5
229940088623 biologically active substance Drugs 0.000 description 5
239000003433 contraceptive agent Substances 0.000 description 5
239000000017 hydrogel Substances 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
230000001965 increasing effect Effects 0.000 description 5
230000006698 induction Effects 0.000 description 5
239000007788 liquid Substances 0.000 description 5
238000011068 loading method Methods 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
235000010290 biphenyl Nutrition 0.000 description 4
239000004305 biphenyl Substances 0.000 description 4
RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
238000005259 measurement Methods 0.000 description 4
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
239000003960 organic solvent Substances 0.000 description 4
ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
229920000573 polyethylene Polymers 0.000 description 4
239000002904 solvent Substances 0.000 description 4
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
JPYHHZQJCSQRJY-UHFFFAOYSA-N Phloroglucinol Natural products CCC=CCC=CCC=CCC=CCCCCC(=O)C1=C(O)C=C(O)C=C1O JPYHHZQJCSQRJY-UHFFFAOYSA-N 0.000 description 3
ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
125000003118 aryl group Chemical group 0.000 description 3
230000036760 body temperature Effects 0.000 description 3
230000002254 contraceptive effect Effects 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
238000010438 heat treatment Methods 0.000 description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
239000002609 medium Substances 0.000 description 3
QCDYQQDYXPDABM-UHFFFAOYSA-N phloroglucinol Chemical compound OC1=CC(O)=CC(O)=C1 QCDYQQDYXPDABM-UHFFFAOYSA-N 0.000 description 3
229960001553 phloroglucinol Drugs 0.000 description 3
NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
238000005303 weighing Methods 0.000 description 3
YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
229920001730 Moisture cure polyurethane Polymers 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000011149 active material Substances 0.000 description 2
239000003125 aqueous solvent Substances 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
229940124558 contraceptive agent Drugs 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
229940000033 dermatological agent Drugs 0.000 description 2
239000003241 dermatological agent Substances 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
238000002481 ethanol extraction Methods 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
230000001976 improved effect Effects 0.000 description 2
RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000008055 phosphate buffer solution Substances 0.000 description 2
229920001748 polybutylene Polymers 0.000 description 2
229920001451 polypropylene glycol Polymers 0.000 description 2
229940064911 prostin e2 Drugs 0.000 description 2
WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 2
230000005070 ripening Effects 0.000 description 2
238000003860 storage Methods 0.000 description 2
239000003860 topical agent Substances 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
229940113165 trimethylolpropane Drugs 0.000 description 2
150000004072 triols Chemical class 0.000 description 2
239000011240 wet gel Substances 0.000 description 2
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
208000020925 Bipolar disease Diseases 0.000 description 1
108090000317 Chymotrypsin Proteins 0.000 description 1
208000034423 Delivery Diseases 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
241000282412 Homo Species 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
WDNUQBZUAGLXPQ-UHFFFAOYSA-N N=C=O.N=C=O.C1CCCCC1.C1CCCCC1.C Chemical compound N=C=O.N=C=O.C1CCCCC1.C1CCCCC1.C WDNUQBZUAGLXPQ-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
101100114416 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) con-10 gene Proteins 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
239000000150 Sympathomimetic Substances 0.000 description 1
AKGUXECGGCUDCV-UXBLZVDNSA-N [(e)-benzylideneamino]urea Chemical compound NC(=O)N\N=C\C1=CC=CC=C1 AKGUXECGGCUDCV-UXBLZVDNSA-N 0.000 description 1
206010000210 abortion Diseases 0.000 description 1
231100000176 abortion Toxicity 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
230000036592 analgesia Effects 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
230000001548 androgenic effect Effects 0.000 description 1
230000000954 anitussive effect Effects 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000001773 anti-convulsant effect Effects 0.000 description 1
230000001387 anti-histamine Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000000078 anti-malarial effect Effects 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
229940125681 anticonvulsant agent Drugs 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000003430 antimalarial agent Substances 0.000 description 1
229940033495 antimalarials Drugs 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000003096 antiparasitic agent Substances 0.000 description 1
229940125687 antiparasitic agent Drugs 0.000 description 1
229940125688 antiparkinson agent Drugs 0.000 description 1
239000000939 antiparkinson agent Substances 0.000 description 1
239000003434 antitussive agent Substances 0.000 description 1
229940124584 antitussives Drugs 0.000 description 1
239000003699 antiulcer agent Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
208000028683 bipolar I disease Diseases 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
238000009835 boiling Methods 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
229930188620 butyrolactone Natural products 0.000 description 1
229940125692 cardiovascular agent Drugs 0.000 description 1
239000002327 cardiovascular agent Substances 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
210000003679 cervix uteri Anatomy 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
UXTMROKLAAOEQO-UHFFFAOYSA-N chloroform;ethanol Chemical compound CCO.ClC(Cl)Cl UXTMROKLAAOEQO-UHFFFAOYSA-N 0.000 description 1
229960002376 chymotrypsin Drugs 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
238000005336 cracking Methods 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
229920003020 cross-linked polyethylene Polymers 0.000 description 1
239000004703 cross-linked polyethylene Substances 0.000 description 1
125000004956 cyclohexylene group Chemical group 0.000 description 1
KORSJDCBLAPZEQ-UHFFFAOYSA-N dicyclohexylmethane-4,4'-diisocyanate Chemical compound C1CC(N=C=O)CCC1CC1CCC(N=C=O)CC1 KORSJDCBLAPZEQ-UHFFFAOYSA-N 0.000 description 1
238000000113 differential scanning calorimetry Methods 0.000 description 1
150000002009 diols Chemical class 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000004821 distillation Methods 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
230000001076 estrogenic effect Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
210000004996 female reproductive system Anatomy 0.000 description 1
239000006260 foam Substances 0.000 description 1
239000000417 fungicide Substances 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
229920001519 homopolymer Polymers 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
150000002440 hydroxy compounds Chemical class 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
239000003326 hypnotic agent Substances 0.000 description 1
230000000147 hypnotic effect Effects 0.000 description 1
229940126904 hypoglycaemic agent Drugs 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000009027 insemination Effects 0.000 description 1
IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 description 1
HLJDOURGTRAFHE-UHFFFAOYSA-N isocyanic acid;3,5,5-trimethylcyclohex-2-en-1-one Chemical compound N=C=O.N=C=O.CC1=CC(=O)CC(C)(C)C1 HLJDOURGTRAFHE-UHFFFAOYSA-N 0.000 description 1
KCWDJXPPZHMEIK-UHFFFAOYSA-N isocyanic acid;toluene Chemical compound N=C=O.N=C=O.CC1=CC=CC=C1 KCWDJXPPZHMEIK-UHFFFAOYSA-N 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
229960005015 local anesthetics Drugs 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
230000003529 luteolytic effect Effects 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
239000000155 melt Substances 0.000 description 1
KYBOHGVERHWSSV-WUZYGKFZSA-N methyl (e)-7-[(1r,2r,3r)-3-hydroxy-2-[(e,3s)-3-hydroxy-4,4-dimethyloct-1-enyl]-5-oxocyclopentyl]hept-2-enoate Chemical compound CCCCC(C)(C)[C@@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(=O)OC KYBOHGVERHWSSV-WUZYGKFZSA-N 0.000 description 1
HOJJZXINRFKRGT-NKLQCYAOSA-N methyl (z)-7-[(1r,2r,3r)-3-hydroxy-2-[(e)-3-hydroxy-4,4-dimethyloct-1-enyl]-5-oxocyclopentyl]hept-5-enoate Chemical compound CCCCC(C)(C)C(O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(=O)OC HOJJZXINRFKRGT-NKLQCYAOSA-N 0.000 description 1
229940095102 methyl benzoate Drugs 0.000 description 1
229960000282 metronidazole Drugs 0.000 description 1
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
244000000010 microbial pathogen Species 0.000 description 1
229940035363 muscle relaxants Drugs 0.000 description 1
239000003158 myorelaxant agent Substances 0.000 description 1
230000001069 nematicidal effect Effects 0.000 description 1
239000005645 nematicide Substances 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
239000011356 non-aqueous organic solvent Substances 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
239000003791 organic solvent mixture Substances 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
244000052769 pathogen Species 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
150000003166 prostaglandin E2 derivatives Chemical class 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
229940079877 pyrogallol Drugs 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
229940125723 sedative agent Drugs 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
239000002195 soluble material Substances 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000007858 starting material Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000003756 stirring Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
UQZVCDCIMBLVNR-TWYODKAFSA-N sulprostone Chemical compound O[C@@H]1CC(=O)[C@H](C\C=C/CCCC(=O)NS(=O)(=O)C)[C@H]1\C=C\[C@@H](O)COC1=CC=CC=C1 UQZVCDCIMBLVNR-TWYODKAFSA-N 0.000 description 1
229960003400 sulprostone Drugs 0.000 description 1
229940127230 sympathomimetic drug Drugs 0.000 description 1
239000003826 tablet Substances 0.000 description 1
IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
AVWRKZWQTYIKIY-UHFFFAOYSA-N urea-1-carboxylic acid Chemical group NC(=O)NC(O)=O AVWRKZWQTYIKIY-UHFFFAOYSA-N 0.000 description 1
230000009677 vaginal delivery Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/48—Polyethers
- C08G18/4833—Polyethers containing oxyethylene units
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/65—Low-molecular-weight compounds having active hydrogen with high-molecular-weight compounds having active hydrogen
- C08G18/66—Compounds of groups C08G18/42, C08G18/48, or C08G18/52
- C08G18/6666—Compounds of group C08G18/48 or C08G18/52
- C08G18/667—Compounds of group C08G18/48 or C08G18/52 with compounds of group C08G18/32 or polyamines of C08G18/38
- C08G18/6674—Compounds of group C08G18/48 or C08G18/52 with compounds of group C08G18/32 or polyamines of C08G18/38 with compounds of group C08G18/3203
- C08G18/6677—Compounds of group C08G18/48 or C08G18/52 with compounds of group C08G18/32 or polyamines of C08G18/38 with compounds of group C08G18/3203 having at least three hydroxy groups
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G2210/00—Compositions for preparing hydrogels
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G2250/00—Compositions for preparing crystalline polymers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Reproductive Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Gynecology & Obstetrics (AREA)
Polymers & Plastics (AREA)
Urology & Nephrology (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Lubricants (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Structures Of Non-Positive Displacement Pumps (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Fluid-Damping Devices (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

NZ193221A 1979-03-21 1980-03-21 Controlled release composition NZ193221A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB7909853		1979-03-21

Publications (1)

Publication Number	Publication Date
NZ193221A true NZ193221A (en)	1984-08-24

Family

ID=10504015

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NZ193221A NZ193221A (en)	1979-03-21	1980-03-21	Controlled release composition
NZ193222A NZ193222A (en)	1979-03-21	1980-03-21	Controlled release composition

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NZ193222A NZ193222A (en)	1979-03-21	1980-03-21	Controlled release composition

Country Status (11)

Country	Link
US (2)	US4931288A (2)
EP (2)	EP0016654B1 (2)
JP (2)	JPH0323530B2 (2)
AT (2)	ATE15444T1 (2)
AU (2)	AU537741B2 (2)
DE (2)	DE3071070D1 (2)
GB (2)	GB2047093B (2)
HK (2)	HK79785A (2)
NZ (2)	NZ193221A (2)
WO (2)	WO1980001985A1 (2)
ZA (2)	ZA801654B (2)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5079009A (en) *	1979-03-21	1992-01-07	National Research Development Corporation	Controlled release compositions including polyethylene oxide with urethane cross-linking
NZ197543A (en) *	1980-07-02	1984-12-14	Commw Scient Ind Res Org	Controlled release compositions for inclusion in intraruminal devices
US4466936A (en) *	1981-02-03	1984-08-21	Bayer Aktiengesellschaft	Production of molds using gel compositions with depot action based on a polyurethane matrix and relatively high molecular weight polyols
AU558611B2 (en) *	1981-02-03	1987-02-05	Bayer Aktiengesellschaft	Polyurethane gel
GB2100269B (en) *	1981-06-12	1985-06-12	Nat Res Dev	Preparation of particulate gels
GB2108517B (en) *	1981-06-12	1985-06-12	Nat Res Dev	Hydrogels
ZA831186B (en) *	1982-03-22	1983-11-30	Upjohn Ltd	Gelled pge2/triacetin solutions
US4443428A (en) *	1982-06-21	1984-04-17	Euroceltique, S.A.	Extended action controlled release compositions
FR2539135B1 (fr) *	1983-01-11	1986-02-28	Essilor Int	Hydrogels de polyurethane et procede de fabrication
GB2135881B (en) *	1983-03-02	1986-09-17	Erba Farmitalia	Pharmaceutical compositions for inhibiting or reducing gastrointestinal side effects of non-steroidal anti-inflammatory drugs
ATE40561T1 (de) *	1983-07-21	1989-02-15	Troponwerke Gmbh & Co Kg	Antiphlogistika enthaltende thermoplastische kunststoffe.
GB8319766D0 (en) *	1983-07-22	1983-08-24	Graham N B	Controlled release device
IL72041A (en) *	1984-06-05	1990-01-18	Elka Touitou	Preparation for controlled release of iodine
US5439966A (en) *	1984-07-12	1995-08-08	National Research Development Corporation	Polyethylene oxide temperature - or fluid-sensitive shape memory device
FR2582944B1 (fr) *	1985-06-11	1990-10-26	Commissariat Energie Atomique	Piece en polymere, notamment en polyurethane de polyoxyethylene a gonflement anisotrope, son procede de fabrication et son utilisation comme dilatateur du col uterin
EP0347145A3 (en) *	1988-06-14	1990-10-24	University Of Utah Research Foundation	Heterogeneous interpenetrating polymer networks for the controlled release of drugs
US5342624A (en) *	1989-02-16	1994-08-30	British Technology Group Ltd.	Dispensing device
ES2072976T3 (es) *	1989-03-17	1995-08-01	Ono Pharmaceutical Co	Poliuretanos biodegradables.
US5225514A (en) *	1989-03-17	1993-07-06	Ono Pharmaceutical Co., Ltd.	Azo containing polyurethanes for drug delivery to the large intestines
GB8918589D0 (en) *	1989-08-15	1989-09-27	Graham Neil B	Polymeric compositions
US5833665A (en) *	1990-06-14	1998-11-10	Integra Lifesciences I, Ltd.	Polyurethane-biopolymer composite
JP2611073B2 (ja) *	1990-07-26	1997-05-21	モンサントカンパニー	新規ポリアミンの製造方法
AU653771B2 (en) *	1991-01-03	1994-10-13	Alkermes Controlled Therapeutics, Inc.	Stabilization of proteins by cationic biopolymers
GB2254002B (en) *	1991-01-16	1995-03-22	Controlled Therapeutics	Retrievable pessary
GB9101502D0 (en) *	1991-01-23	1991-03-06	Controlled Therapeutics Sct	Controlled release compositions
US5273742A (en) *	1991-12-30	1993-12-28	Tyndale Plains-Hunter Ltd.	Biomedical water soluble hydrophilic polyurethane polymers and method of use thereof
GB9313017D0 (en) *	1993-06-24	1993-08-11	Univ Strathclyde	Measurement of water content
US5458879A (en) *	1994-03-03	1995-10-17	The Procter & Gamble Company	Oral vehicle compositions
US6322815B1 (en)	1994-07-22	2001-11-27	W. Mark Saltzman	Multipart drug delivery system
GB9418483D0 (en) *	1994-09-14	1994-11-02	British Tech Group	Compound for use in pre-term labour
GB2306325B (en) *	1994-11-25	1997-09-10	William Leslie Porter	Bolus for supplying biologically beneficial substances to ruminant animals
GB9506946D0 (en) *	1995-04-04	1995-05-24	Univ Strathclyde	Microgels
US20020064546A1 (en) *	1996-09-13	2002-05-30	J. Milton Harris	Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
US6258351B1 (en)	1996-11-06	2001-07-10	Shearwater Corporation	Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
DE19734538C1 (de) *	1997-07-30	1998-12-24	Jenapharm Gmbh	Bioadhäsive Tablette
WO1999034833A1 (en)	1998-01-07	1999-07-15	Shearwater Polymers, Incorporated	Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom
US6514534B1 (en)	1998-08-14	2003-02-04	Incept Llc	Methods for forming regional tissue adherent barriers and drug delivery systems
GB9826192D0 (en) *	1998-12-01	1999-01-20	Controlled Theraputics Scotlan	Oral transmucosal delivery
TWI246524B (en)	2001-01-19	2006-01-01	Shearwater Corp	Multi-arm block copolymers as drug delivery vehicles
US7265186B2 (en) *	2001-01-19	2007-09-04	Nektar Therapeutics Al, Corporation	Multi-arm block copolymers as drug delivery vehicles
GB0222522D0 (en)	2002-09-27	2002-11-06	Controlled Therapeutics Sct	Water-swellable polymers
US7312301B2 (en) *	2002-12-31	2007-12-25	Nektar Therapeutics Al, Corporation	Methods for the formation of hydrogels using thiosulfonate compositions and uses thereof
EP1644473B1 (en)	2003-06-03	2014-01-15	Cantimer Incorporated	Phase change sensor
US20040259744A1 (en) *	2003-12-19	2004-12-23	Meidong Yang	Skin and hair cleansers containing sulfur
ATE385423T1 (de) *	2004-06-16	2008-02-15	Straumann Holding Ag	Abdeckmembran
US7282584B2 (en) *	2004-06-16	2007-10-16	Straumann Holding Ag	Methylene blue
GB0417401D0 (en)	2004-08-05	2004-09-08	Controlled Therapeutics Sct	Stabilised prostaglandin composition
WO2006133048A2 (en) *	2005-06-03	2006-12-14	Duramed Pharmaceuticals, Inc.	Pharmaceutical compositions comprising prostanoid-receptor agonists and methods of making and using the same
US8568705B2 (en)	2005-07-18	2013-10-29	Nektar Therapeutics	Method for preparing branched functionalized polymers using branched polyol cores
DE102005053066A1 (de) *	2005-11-04	2007-05-10	Basf Ag	Verwendung von Copolymeren als Solubilisatoren für in Wasser schwerlöslichen Verbindungen
JP2009523119A (ja) *	2005-12-09	2009-06-18	ビーエーエスエフソシエタス・ヨーロピア	水に溶けにくい化合物のための可溶化剤としてのポリビニルラクタム−ポリオキシアルキレンブロックコポリマーの使用
GB0613333D0 (en)	2006-07-05	2006-08-16	Controlled Therapeutics Sct	Hydrophilic polyurethane compositions
GB0613638D0 (en)	2006-07-08	2006-08-16	Controlled Therapeutics Sct	Polyurethane elastomers
WO2008007098A2 (en) *	2006-07-12	2008-01-17	Controlled Therapeutics (Scotland) Ltd.	Drug delivery polymer with hydrochloride salt of clindamycin
GB0620685D0 (en)	2006-10-18	2006-11-29	Controlled Therapeutics Sct	Bioresorbable polymers
US20100204425A1 (en) *	2007-07-26	2010-08-12	Basf Se	Process for preparing copolymers obtained by graft polymerization in solution and based on polyethers in solid form
EP2244782A4 (en)	2008-01-25	2011-09-14	Univ Utah Res Found	POLYMER WITH LINEAR ORDER RELEASE
DE102009052948B4 (de) *	2009-11-12	2013-05-29	Rkw Se	Silageabdeckung
US9205089B2 (en)	2011-04-29	2015-12-08	Massachusetts Institute Of Technology	Layer processing for pharmaceuticals
GB201110601D0 (en)	2011-06-23	2011-08-03	Controlled Therapeutics Scotland Ltd	Improved bioresorbable
CA2880260A1 (en)	2012-07-26	2014-01-30	Ferring B.V.	Misoprostol formulation
EP2689781A1 (en)	2012-07-26	2014-01-29	Ferring B.V.	Misoprostol composition
EP2754443A1 (en)	2013-01-09	2014-07-16	Ferring B.V.	Misoprostol for the induction of labour
EP2689802A1 (en)	2012-07-26	2014-01-29	Ferring B.V.	Misoprostol formulation
EP2754442A1 (en)	2013-01-09	2014-07-16	Ferring B.V.	Misoprostol for the induction of labour
EA031594B1 (ru)	2012-07-26	2019-01-31	Ферринг Б.В.	Способ уменьшения дородового применения окситоцина и применение внутривлагалищного вкладыша по указанному назначению
WO2015179461A1 (en) *	2014-05-20	2015-11-26	Massachusetts Institute Of Technology	Plasticity induced bonding
GB201916808D0 (en)	2019-11-19	2020-01-01	Ferring Bv	Pharmaceutical delivery device

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES335314A1 (es) *	1966-01-06	1967-12-01	Ceskoslovenska Akademie Ved	Mejoras introducidas en la preparacion de vehiculos insolubles de sustancias al menos parcialmente solubles, biologicamente activas.
US3975350A (en) *	1972-08-02	1976-08-17	Princeton Polymer Laboratories, Incorporated	Hydrophilic or hydrogel carrier systems such as coatings, body implants and other articles
US3822238A (en) *	1972-08-02	1974-07-02	Princeton Polymer Lab	Hydrophilic polyurethane polymers
US3953406A (en) *	1973-01-26	1976-04-27	California Institute Of Technology	Water-insoluble, swellable polyurethanes
US3993551A (en) *	1973-09-10	1976-11-23	Union Carbide Corporation	Process for cocrosslinking water soluble polymers and products thereof
FR2250793B1 (2) *	1973-11-09	1978-12-29	Commissariat Energie Atomique
GB1494814A (en) *	1976-07-14	1977-12-14	Sanyo Chemical Ind Ltd	Agrochemical compositions
GB1551620A (en) *	1976-12-13	1979-08-30	Ici Ltd	Delivery means for biologically active agents
SE431821B (sv) *	1979-01-29	1984-03-05	Perstorp Ab	Lagringsstabilt, prostaglandininnehallande medicinskt preparat

1980
- 1980-03-21 AU AU56691/80A patent/AU537741B2/en not_active Expired
- 1980-03-21 DE DE8080300904T patent/DE3071070D1/de not_active Expired
- 1980-03-21 WO PCT/GB1980/000050 patent/WO1980001985A1/en not_active Ceased
- 1980-03-21 AU AU56690/80A patent/AU537740B2/en not_active Expired
- 1980-03-21 JP JP55500625A patent/JPH0323530B2/ja not_active Expired - Lifetime
- 1980-03-21 AT AT80300904T patent/ATE15444T1/de not_active IP Right Cessation
- 1980-03-21 EP EP80300904A patent/EP0016654B1/en not_active Expired
- 1980-03-21 WO PCT/GB1980/000049 patent/WO1980001984A1/en not_active Ceased
- 1980-03-21 AT AT80300900T patent/ATE14979T1/de active
- 1980-03-21 GB GB8009637A patent/GB2047093B/en not_active Expired
- 1980-03-21 NZ NZ193221A patent/NZ193221A/en unknown
- 1980-03-21 ZA ZA00801654A patent/ZA801654B/xx unknown
- 1980-03-21 ZA ZA00801659A patent/ZA801659B/xx unknown
- 1980-03-21 GB GB8009638A patent/GB2047094B/en not_active Expired
- 1980-03-21 EP EP80300900A patent/EP0016652B1/en not_active Expired
- 1980-03-21 JP JP55500624A patent/JPH0323529B2/ja not_active Expired - Lifetime
- 1980-03-21 NZ NZ193222A patent/NZ193222A/en unknown
- 1980-03-21 DE DE8080300900T patent/DE3071006D1/de not_active Expired
1985
- 1985-10-17 HK HK797/85A patent/HK79785A/xx not_active IP Right Cessation
- 1985-10-17 HK HK798/85A patent/HK79885A/xx not_active IP Right Cessation
1988
- 1988-04-29 US US07/188,674 patent/US4931288A/en not_active Expired - Lifetime
- 1988-06-14 US US07/208,849 patent/US4894238A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP0016652B1 (en)	1985-08-21
WO1980001984A1 (en)	1980-10-02
GB2047093B (en)	1983-12-07
HK79885A (en)	1985-10-25
US4894238A (en)	1990-01-16
JPH0323530B2 (2)	1991-03-29
HK79785A (en)	1985-10-25
ZA801659B (en)	1981-10-28
ATE14979T1 (de)	1985-09-15
EP0016652A1 (en)	1980-10-01
DE3071006D1 (en)	1985-09-26
ATE15444T1 (de)	1985-09-15
AU537740B2 (en)	1984-07-12
JPS56500253A (2)	1981-03-05
GB2047093A (en)	1980-11-26
AU537741B2 (en)	1984-07-12
EP0016654B1 (en)	1985-09-11
WO1980001985A1 (en)	1980-10-02
EP0016654A1 (en)	1980-10-01
AU5669180A (en)	1980-09-25
JPS56500254A (2)	1981-03-05
GB2047094A (en)	1980-11-26
GB2047094B (en)	1983-12-07
AU5669080A (en)	1980-09-25
US4931288A (en)	1990-06-05
NZ193222A (en)	1984-08-24
DE3071070D1 (en)	1985-10-17
ZA801654B (en)	1981-10-28
JPH0323529B2 (2)	1991-03-29

Publication	Publication Date	Title
US4931288A (en)	1990-06-05	Controlled release compositions (II)
US4235988A (en)	1980-11-25	Delivery means for biologically active agents
JP3859700B2 (ja)	2006-12-20	ランダムブロツクコポリマー
US4584188A (en)	1986-04-22	Hydrogels
CA1085726A (en)	1980-09-16	Polyoxyalkylene-polyurethane medicament delivery means
US5728762A (en)	1998-03-17	Polyether polyurethane polymers, gels, solutions and uses thereof
EP0132384B1 (en)	1990-09-26	Controlled release device
US5017382A (en)	1991-05-21	Controlled release compositions (II)
US5932200A (en)	1999-08-03	Polyether polyurethane polymers, gels, solutions and uses thereof
DE69013926T2 (de)	1995-03-23	Polymerwerkstoffe.
BRPI0713630A2 (pt)	2012-10-30	polìmero linear intumescìvel em água para produzir o mesmo, e, composição de liberação controlada
DE2528068A1 (de)	1976-01-08	Wasserunloesliche hydrophile copolymere
CA2575933A1 (en)	2006-02-09	Stabilised prostaglandin composition
US5135964A (en)	1992-08-04	Ultraviolet cured peelable film and method therefor
US5079009A (en)	1992-01-07	Controlled release compositions including polyethylene oxide with urethane cross-linking
WO2012066000A1 (en)	2012-05-24	Intravaginal drug delivery device comprising a polyurethane copolymer
Graham et al.	1985	The release of prostaglandin E2 from a novel crystalline-rubbery poly (ethylene oxide) network crosslinked by 3, 4-dihydro-2H-pyranyl-2-methyl-(3, 4-dihydro-2H-pyran-2-carboxylate)
CA1242394A (en)	1988-09-27	Controlled release device